Purpose of review: Eosinophilic esophagitis (EoE) is a chronic inflammatory disease of the oesophagus whose incidence is on the rise. Despite maximal use of guideline-based therapies including food elimination diets and steroids, many patients remain symptomatic. This review serves to summarize safety and efficacy of monoclonal antibodies in treatment of EoE.
Recent findings: There has been an increasing number of biologics under consideration for EoE and several that have undergone clinical trials. mAbs that target specific effectors involved in the disease may offer additional clinical and histologic benefit. In addition, they offer a more benign adverse effect profile than traditional therapies.
Summary: Biologics for treatment of EoE may result in symptom and histologic improvement and has the potential to treat disease with minimal side effects.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.